Prospective Study of Gut Hormone and Metabolic Changes After Adjustable Gastric Banding and Roux-en-Y Gastric Bypass

Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
International journal of obesity (2005) (Impact Factor: 5). 05/2009; 33(7):786-95. DOI: 10.1038/ijo.2009.79
Source: PubMed


The objective of this study was to quantify hormones that regulate energy and glucose homeostasis to establish possible mechanisms for the greater efficacy of Roux-en-Y gastric bypass (RYGB) compared with laparoscopic adjustable gastric banding (LAGB) in achieving weight loss and improved insulin sensitivity.
Longitudinal study of patients undergoing LAGB (n=15) and RYGB (n=28) who were studied before surgery and at 2, 12, 26 and 52 weeks afterwards.
Fasting blood samples were drawn at each visit. Postprandial blood samples were also obtained before surgery and at 26 and 52 weeks. Samples were assayed for peptide YY (PYY), ghrelin, glucagon-like peptide-1 (GLP-1), glucose, insulin, leptin, thyrotropic hormone, free T(4) and free T(3).Results:At 1 year there was greater weight loss in RYGB compared with LAGB patients (30 vs 15%), but final body mass index was similar (34 vs 33 kg m(-2)). At week 52, area under the curve (AUC) for PYY in RYGB subjects was greater than LAGB (P<0.01). GLP-1 levels at 30 min after meal were threefold greater after RYGB compared with LAGB (P<0.001). Conversely, ghrelin AUC increased after LAGB at week 52 (P<0.05) but tended to decrease after RYGB. Fasting glucose, insulin, and leptin and homeostasis model of assessment (HOMA-IR) decreased in both groups over time but were significantly lower at week 52 after RYGB compared with LAGB. The change in leptin correlated significantly with weight loss in LAGB (r=0.86) and RYGB (r=0.77), however, HOMA-IR correlated significantly with weight loss only in LAGB (r=0.78), and not RYGB (r=0.15). There was a significant decrease in free T(3) (P<0.01) after RYGB.
Differences in levels of gut hormones may play a role in promoting greater weight loss and insulin sensitivity after RYGB compared with LAGB, however, weight loss may be limited by decreases in free T(3) and leptin.


Available from: Donald J Mcmahon
    • "In comparison to the hormonal changes observed post- RYGB, GLP-1, OXM, and PYY levels are unchanged or decreased following calorie restriction-induced weight loss and unchanged following LGB [80] [81]. This may explain the superiority of RYGB over LGB and calorie restriction in inducing weight loss. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is on the rise and the pursuit of efficient and safe treatment is ongoing. Available anti-obesity medical therapies have so far proved to be disappointing, whereas bariatric surgery is leading the way and offers long-term health benefits. Part of the success of bariatric surgery is thought to be mediated by gut hormones. A better understanding of the role of gut hormones within the gut-brain signaling pathway in the control of hunger, satiety, and energy homeostasis, has led to their therapeutic exploitation as possible anti-obesity drugs. In this review, we provide a summary of currently available treatment options for obesity from simple lifestyle modifications and bariatric surgery to traditional and novel medical therapies.
    Postgraduate Medicine 06/2015; 127(5):494-502. DOI:10.1080/00325481.2015.1048181 · 1.70 Impact Factor
  • Source
    • "Additionally, our findings most likely reflect post-RYGB metabolic and endocrine changes that impact the sensitivity of the brain to alcohol reward. Notably, hormones that have been shown to change after RYGB, such as leptin and ghrelin [26], [27], [28], are also known to modulate the dopaminergic reward system [29], [30], [31] as well as EtOH consumption [32], [33]. Thus, it is conceivable that RYGB may reverse blunted ghrelin signaling in obesity [34], [35], which acting upstream on the dopamine neurons [36], [37], [38], may alleviate reward deficits associated with dietary obesity [39]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Roux-en-Y gastric bypass surgery (RYGB) is an effective treatment for severe obesity. Clinical studies however have reported susceptibility to increased alcohol use after RYGB, and preclinical studies have shown increased alcohol intake in obese rats after RYGB. This could reflect a direct enhancement of alcohol's rewarding effects in the brain or an indirect effect due to increased alcohol absorption after RGYB. To rule out the contribution that changes in alcohol absorption have on its rewarding effects, here we assessed the effects of RYGB on intravenously (IV) administered ethanol (1%). For this purpose, high fat (60% kcal from fat) diet-induced obese male Sprague Dawley rats were tested ∼2 months after RYGB or sham surgery (SHAM) using both fixed and progressive ratio schedules of reinforcement to evaluate if RGYB modified the reinforcing effects of IV ethanol. Compared to SHAM, RYGB rats made significantly more active spout responses to earn IV ethanol during the fixed ratio schedule, and achieved higher breakpoints during the progressive ratio schedule. Although additional studies are needed, our results provide preliminary evidence that RYGB increases the rewarding effects of alcohol independent of its effects on alcohol absorption.
    PLoS ONE 12/2013; 8(12):e83741. DOI:10.1371/journal.pone.0083741 · 3.23 Impact Factor
  • Source
    • "However, in a rodent model, postoperative weight loss was correlated with the magnitude of decrease in ghrelin levels [74]. Similar to weight loss induced by lifestyle alterations, the degree of leptin decrease at 1 y after RYGB has been found to correlate with the degree of weight loss [36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Substantial heterogeneity exists in weight loss trajectories amongst patients following bariatric surgery. Hormonal factors are postulated to be amongst the contributors to the variation seen. Several hormones involved in hunger, satiety, and energy balance are affected by bariatric surgery, with the alteration in hormonal milieu varying by procedure. Limited research has been conducted to examine potential hormonal mediators of weight loss failure or recidivism following bariatric surgery. While hormonal factors that influence weight loss success following gastric banding have not been identified, data suggest that hormonal factors may be involved in modulating weight loss success following gastric bypass. There may be hormonal mediators involved in determining the weight trajectory following sleeve gastrectomy, though the extremely limited data currently available prohibits definitive conclusions from being drawn. There is great need for future research studies to explore this knowledge gap, as improving this knowledge base could be of benefit to guide clinicians toward understanding the hormonal contributors to a patient's postoperative weight loss failure or recidivism or perhaps be of value in selecting the most appropriate bariatric procedure based on the preoperative hormone milieu. Integrative interdisciplinary approaches exploring these complex interrelationships could potentially increase the explanatory power of such investigations.
    Gastroenterology Research and Practice 10/2013; 2013(8):528450. DOI:10.1155/2013/528450 · 1.75 Impact Factor
Show more